Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New wireless catheter could spot hidden heart disease in chest pain patients

NCT ID NCT07453381

Diagnosis Sponsor: Peking University Third Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tests a new wireless pressure microcatheter to diagnose coronary microvascular dysfunction (CMD) in people with chest pain but no major artery blockages. Researchers will compare the device's measurements to heart MRI scans in 114 participants. If accurate, it could offer a simpler way to detect this often-missed condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
multi-sensor wireless pressure microcatheter
What this could lead to
If successful, this could provide a more accurate and less invasive way to diagnose coronary microvascular dysfunction, helping doctors identify the cause of chest pain in patients with clear arteries.
What could go wrong
This is an early-stage study with only 114 participants, and the device's accuracy is being compared to an imaging reference. It may not prove superior or widely applicable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 114 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study aims to enroll patients with angina symptoms or objective evidence of myocardial ischemia, whose coronary angiography visual assessment shows a diameter stenosis of \<50% and an FFR \>0.8 (or cRR \>0.89).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years, gender not limited; 2. Symptoms of angina pectoris, or objective evidence of myocardial ischemia (e.g., electrocardiogram, myocardial injury markers, etc.); 3. Visual assessment of coronary angiography shows diameter stenosis \< 50% and FFR \> 0.8 (or cRR \> 0.89); 4. Microvascular function assessment is planned; 5. Agree to participate in this clinical study and voluntarily sign the informed consent form. Exclusion Criteria: 1. Acute myocardial infarction, PCI, CABG, or valvular surgery following angiography within the past 30 days; 2. Severe valvular disease requiring surgical or interventional treatment; 3. Chest pain with known non-ischemic causes (e.g., pericarditis, pulmonary hypertension, esophageal spasm); 4. Contraindications to CMR (e.g., certain types of pacemakers or defibrillators, severe claustrophobia); 5. Clear contraindications to adenosine and ATP use (e.g., second- or third-degree atrioventricular block, sick sinus syndrome, severe asthma, systolic blood pressure below 90 mmHg); 6. Renal insufficiency (eGFR ≤ 45 mL/min/1.73 m2) or currently undergoing dialysis; 7. Severe heart failure or LVEF ≤ 35%; 8. Severe organ disease or life expectancy less than 2 years; 9. Known to be participating in other drug or device clinical trials that have not yet met the primary endpoint; 10. Other investigators deem the candidate unsuitable for this clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary microvascular dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary microvascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary microvascular dysfunction (CMD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    5 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Beijing Anzhen Hospital.Capital Medical University

    RECRUITING

    Beijing, China

  • Cangzhou Central Hospital

    NOT_YET_RECRUITING

    Cangzhou, Hebei, China

  • Chengdu Second People's Hospital

    NOT_YET_RECRUITING

    Chengdu, Sichuan, China

  • Peking University Third Hospital

    RECRUITING

    Beijing, China

    Contact Email: •••••@•••••

  • Wang Jing Hospital Of CACMS（China Academy of Chinese Medical Sciences）

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100102, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.